Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) CTO Seshu Tyagarajan sold 14,322 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the completion of the transaction, the chief technology officer now owns 96,790 shares of the company’s stock, valued at $698,823.80. The trade was a 12.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Seshu Tyagarajan also recently made the following trade(s):

• On Friday, November 29th, Seshu Tyagarajan sold 20,392 shares of Candel Therapeutics stock. The shares were sold at an average price of $4.56, for a total value of $92,987.52.

Candel Therapeutics Trading Down 13.4 %

Shares of Candel Therapeutics stock opened at $6.66 on Friday. The business has a 50-day moving average price of $6.61 and a two-hundred day moving average price of $6.28. Candel Therapeutics, Inc. has a 1-year low of $1.16 and a 1-year high of $14.60. The company has a market cap of $216.32 million, a P/E ratio of -3.85 and a beta of -1.20.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price (up from $11.00) on shares of Candel Therapeutics in a research report on Wednesday, December 18th.

Institutional Trading of Candel Therapeutics

A number of large investors have recently bought and sold shares of the business. HB Wealth Management LLC grew its holdings in Candel Therapeutics by 54.1% during the 4th quarter. HB Wealth Management LLC now owns 87,300 shares of the company’s stock worth $696,000 after acquiring an additional 30,642 shares during the period. Barclays PLC grew its stake in shares of Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after buying an additional 21,971 shares during the period. Geode Capital Management LLC grew its stake in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after buying an additional 51,111 shares during the period. State Street Corp grew its stake in shares of Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after buying an additional 19,207 shares during the period. Finally, Atom Investors LP acquired a new stake in shares of Candel Therapeutics in the 3rd quarter valued at about $103,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.